AddedRisk Factors
In October 2025, we received Breakthrough Device Designation from the FDA for the “Breakthrough Device Designation Indications” using our ExomeDxTM and GenomeDxTM tests. Breakthrough Device Designation provides certain benefits, including more interactive and timely communications with FDA staff, potential use of post-market data collection to facilitate expedited development and review, opportunities for more efficient and flexible clinical study design, and prioritized review of premarket submissions. However, there can be no guarantee that these benefits will materialize or significantly impact our development and regulatory authorization process. We may not experience a faster development process, review, or authorization compared to conventional FDA procedures. Breakthrough Device Designation does not alter the regulatory standards for marketing authorization or guarantee that we will ultimately obtain FDA authorization for the Breakthrough Device Designation Indications using our ExomeDxTM and GenomeDxTM tests. Furthermore, the FDA may rescind Breakthrough Device Designation if it believes that the designation is no longer supported by data from our clinical development program. As with all FDA marketing authorizations, we will need to continue to comply with applicable regulations and standards, which may change over time.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedRisk Factors
and foreign requirements for laboratory certification may be costly or difficult to meet and could affect our ability to receive specimens from certain states or foreign countries.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedRisk Factors
portfolio will not be negatively impacted by the decisions described above, rulings in other cases or changes in guidance or procedures issued by the USPTO.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedRisk Factors
Information technology and telecommunications systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious internal or external human acts and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins,
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RemovedRisk Factors
•We may be unable to realize the level of the anticipated benefits that we expect from exiting businesses and restructuring our operations, which may adversely impact our business and results of operations.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
We have estimated the global market opportunity for our current and future products and services, and these markets may be smaller than we estimate.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
•our success in marketing and selling, and changes in demand for, our tests, and the level of reimbursement and collection obtained for such tests;
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
Most recently, on April 29, 2024, the FDA published a final rule on LDTs, in which FDA outlines its plans to end enforcement discretion for many LDTs in five stages over a four-year period. In Phase 1 (effective May 6, 2025), clinical laboratories would be required to comply with medical device (adverse event) reporting, correction/removal reporting, and certain quality systems complaint handling requirements. In Phase 2 (effective May 6, 2026), clinical laboratories would be required to comply with all other device requirements (e.g., registration/listing, labeling, investigational use), except for remaining quality systems requirements and premarket review. In Phase 3 (effective May 6, 2027), clinical laboratories would be required to comply with all remaining applicable quality systems requirements. In Phase 4 (effective November 6, 2027), clinical laboratories would be
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
required to comply with premarket submission requirements for high-risk tests (i.e., tests subject to premarket approval (PMA) requirement). Finally, in Phase 5 (effective May 6, 2028), clinical laboratories would be required to comply with premarket submission requirements for moderate- and low-risk tests (i.e., tests subject to de novo or 510(k) requirement). The final rule potentially extends enforcement discretion for certain tests – e.g., LDTs approved by the New York State Department of Health, and LDTs first marketed prior to May 6, 2024 which are not modified or are modified in certain limited ways – from certain FDA regulatory requirements, provided certain important limitations have been met. We are actively reviewing the final rule to evaluate its applicability to our operations, and the extent to which we may be required to modify our operations to comply with its requirements.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
Multiple lawsuits have been filed challenging the FDA’s authority to regulate LDTs as medical devices under the Federal Food, Drug, and Cosmetic Act. The outcome of these lawsuits is uncertain at this time.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
program, and payments may be recouped by CMS if it is determined that they were improperly made. Currently, a small percentage of our revenues are generated by payments from Medicare.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
The price of our securities may fluctuate significantly due to general market and economic conditions. An active trading market for our securities may not be sustained. In addition, the price of our securities can vary due to general economic conditions and forecasts, our general business condition and the release of our financial reports. You may be unable to sell your securities when desired or at an acceptable price unless an active trading market can be sustained.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
If we do not meet the expectations of investors, stockholders or financial analysts, the market price of our securities may decline.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
If we do not meet the expectations of investors or securities analysts, the market price of our securities may decline. In addition, fluctuations in the price of our securities could contribute to the loss of all or part of your investment. If an active market for our securities does not continue, the trading price of our securities could be volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control. Any of the risk factors noted in this Annual Report could have a material adverse effect on your investment in our securities and our securities may trade at prices significantly below the price you paid for them. In such circumstances, the trading price of our securities may not recover and may experience a further decline.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
•actual or anticipated fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to us;
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
•the public’s reaction to our press releases, our other public announcements and our filings with the SEC;
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RewordedRisk Factors
If the FDA were ultimately regulates certain LDTs, or we voluntarily choose to determine that submit certain tests offered by us as LDTs are no longer eligible test(s) for enforcement discretion for any reason, including new rules, policies or guidance, or due to changes in statute, FDA review, our tests may become subject to extensive FDA requirements or and our business may otherwise be adversely affected.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
In general, an “ownership change” An ownership change generally occurs if there is a cumulative change in its ownership the percentage of our stock owned by “5% shareholders” that exceeds one or more 5% shareholders increases by more than 50 percentage points over a rolling three-year period.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our If remediation of the material weakness is not effective, or if we fail to maintain effective internal controls control over financial reporting may not be effective reporting, we could have material misstatements in our financial statements, which could have a significant and adverse effect on our business and reputation.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
The stock market in general and Nasdaq have experienced trading price and volume fluctuations that valuation of life sciences companies, including ours, have been and may continue to be highly volatile, which has often been unrelated or disproportionate to the operating performance of the particular companies affected.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
If an author or other third party that distributes such open-source software were to allege that we had not complied with the conditions of one or more of these licenses, we could be required to incur significant legal expenses defending against such allegations.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
The sale and use of our solutions, products and services could lead to product or professional liability claims, including class action lawsuits. lawsuits, and the growth in the sale and use of our solutions, products and services could lead to greater exposure to product or professional liability claims.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
While these guidelines may be subject to review and modification by the USPTO over time, we cannot assure you that our intellectual property strategy or patent portfolio will not be negatively impacted by the decisions described above, rulings in other cases or changes in guidance or procedures issued by the USPTO.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Because EKRA is a relatively new law, there is no agency guidance and only two a few courts have addressed the application of EKRA and those courts reached opposite conclusions. conclusions on the issue of whether laboratory payments to employees for sales and marketing activities implicate or violate EKRA.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
The use of AI applications has resulted in, and may in the future may result in, cybersecurity incidents that implicate the personal medical and genetic data of patients analyzed within in
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
The taxes imposed by new legislation, cost reduction measures and the expansion in the government’s role in the U.S. healthcare industry may result in decreased profits to us, which may adversely affect our business, financial condition and results of operations.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
As of December 31, 2024, our 2025, we had total gross deferred tax assets were of approximately $318 million. $342 million, including net operating loss carryforwards (“NOLs”) and tax credit carryforwards.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Casdin, one of our directors, is affiliated with Casdin Partners and CMLS Holdings, LLC (“CMLS Holdings”), which owned approximately 1% of our outstanding shares of our Class A common stock as of December 31, 2024, Holdings”) and Mr.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Any finding that our patents or applications are unenforceable could or invalid would harm our ability to prevent others from practicing the related technology, and a finding that others have inventorship or ownership rights to our patents and applications could require us to obtain certain rights to practice related technologies, which may not be available on favorable terms, if at all.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
In addition, with the acquisition of Fabric Genomics, we generate revenues through software and interpretation services related to rare disease, hereditary risk, and cancer testing. Our customers include clinical laboratories, hospitals, and research institutions. Our ability to increase this revenue will depend on our ability to expand our customer base among hospitals and genomic centers, along with increased adoption of whole genome sequencing and AI-enabled interpretation in clinical workflows.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
A discussion regarding our financial condition and results of operations for the year ended December 31, 2025 compared to the year ended December 31, 2024 is presented below. A discussion regarding our financial condition and results of operations for the year ended December 31, 2024 compared to the year ended December 31, 2023 can be found in “Management's Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on February 20, 2025.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
General and administrative expenses increased by $46.3 million, or 44%, to $150.8 million for the year ended December 31, 2025, from $104.5 million for the year ended December 31, 2024. The increase was primarily attributable to increased compensation related costs of $33.0 million, higher legal, compliance and consultant related costs of $9.5 million, higher IT software and infrastructure costs of $6.1 million and increased amortization expense for acquired intangible assets established in connection with purchase accounting. These increases were partially offset by a one-time sales-and-use tax refund of $8.4 million.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
We account for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations. The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The estimated fair value of identifiable intangible assets acquired in a business combination is based on third-party valuations that use information and assumptions provided by the Company’s management, which consider estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, royalty rate, estimated cost savings, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RemovedMD&A
General and administrative expenses decreased by $32.6 million, or 24%, to $101.1 million for the year ended December 31, 2024, from $133.8 million for the year ended December 31, 2023. The decrease was attributable to lower current period expenses related to professional services, software and information technology related costs, insurance costs, fixed asset depreciation and personnel-related costs from the now discontinued Legacy Sema4 business.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
Other operating expenses, net were $3.4 million for the year ended December 31, 2024, reflecting related party expenses.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
Other operating expenses, net were $7.2 million for the year ended December 31, 2023 and included related party expenses of $5.3 million and a non-cash charge of $3.6 million to reserve for obsolete Legacy Sema4 inventory, partially offset by a gain of $1.7 million to recognize the sale of certain assets of Legacy Sema4.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
Year Ended December 31, 2024 2023 Revenue $ 305,450 $ 202,566 Cost of services 111,053 112,560 Gross profit 194,397 90,006 Gross margin 64 % 44 % Add: Depreciation and amortization expense $ 4,047 $ 4,350 Stock-based compensation expense 431 (1,217) Restructuring expense 54 139 Adjusted gross profit $ 198,929 $ 93,278 Adjusted gross margin 65 % 46 %
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
Year Ended December 31, 2024 2023 Net loss $ (52,286) $ (175,767) Depreciation and amortization 21,953 33,734 Stock-based compensation expense 9,138 (326) Impairment loss (1) — 10,402 Restructuring costs (2) 1,752 6,532 Change in fair value of warrants and contingent liabilities (3) 13,370 (1,170) Gain on sale of assets (4) — (1,677) Provision for excess and obsolete inventory associated with Legacy Sema4 — 3,634 Gain on debt forgiveness (5) — (2,750) Other (6) 12,789 1,131 Adjusted net income (loss) $ 6,716 $ (126,257)
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
(2)Represents costs incurred for restructuring activities, which include severance, and in the prior period, third-party consulting costs.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
(3)Represents the change in fair market value of the liabilities associated with our public warrants, private placement warrants, Perceptive warrants and the earn-out shares.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
(4)Represents a prior year gain recognized on the sale of certain assets sold as a result of an auction.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
As the market value of our shares of Class A common stock held by non-affiliates was between $250.0 million and $700.0 million as of June 28, 2024 (the last business day of our most recently completed second fiscal quarter) and our revenue for the year ended December 31, 2023 was more than $100.0 million, we continue to be deemed an accelerated filer under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of December 31, 2024. However, we are no longer a “smaller
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
reporting company” and will no longer be eligible to rely on the scaled disclosure exemptions available to smaller reporting companies starting with our first Quarterly Report on Form 10-Q in 2025.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
We are an “emerging growth company” within the meaning of the Jumpstart Our Business Startups Act (the “JOBS Act”). The JOBS Act allows an emerging growth company to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. We have elected to use this extended transition period and, as a result, our financial statements may not be comparable to companies that comply with public company effective dates. We also intend to rely on other exemptions provided by the JOBS Act, including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RewordedMD&A
Net cash used in investing activities during the year ended December 31, 2023 2025 was $43.7 $61.5 million, which included purchases of marketable securities of $47.7 million, $12.1 $32.9 million in consideration held in escrow paid for the Acquisition and $5.3 million in acquisition of Fabric Genomics, purchases of property and equipment, which was offset partially by $17.8 million in proceeds from maturities equipment of $19.0 million, and net marketable securities and $4.0 million in proceeds from the sale activity of assets. $9.6 million.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash used in investing activities during the year ended December 31, 2023 was $43.7 million, which included net marketable securities activity of $29.9 million, purchases of marketable securities property and equipment of $47.7 $5.3 million, and $12.1 million in consideration held in escrow paid for the Acquisition and $5.3 million in purchases of property and equipment, Acquisition, which was partially offset partially by $17.8 million in proceeds from maturities of marketable securities and $4.0 million in of proceeds from the sale of assets.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash provided by financing activities during the year ended December 31, 2024 2025 was $44.2 $48.0 million, which included $46.5 million in primarily reflected proceeds from our prior at-the-market offering (“prior ATM offering, offering”) of $46.7 million, net of issuance costs, partially offset by $2.7 million of finance lease payments and $0.5 million of principal payments on the DECD loan. costs.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Non-operating expense, net of $29.4 $8.1 million for the year ended December 31, 2024 2025 primarily reflected a legal settlement, net settlement of insurance, of $12.8 million, a non-cash charge of $10.1 $4.8 million associated with the exercise of the Perceptive warrant and a non-cash charge of $3.3 $1.2 million to account for the increase in fair value of our warrant financial liabilities.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
The increase was primarily attributable to higher compensation related costs of $16.5 million, which reflects our investment to support growth in our commercial team team, as well as incremental variable billing the inclusion of selling and selling cost marketing costs of Fabric Genomics.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
For the year ended December 31, 2023, represents a gain recognized on the sale of certain assets sold as a result of an auction, principal loan forgiveness under the amendment to the DECD loan, and contract termination costs associated with the now discontinued Legacy Sema4 business.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash used in investing activities during the year ended December 31, 2024 was $30.1 million which included purchases of net marketable securities activity of $66.3 $24.6 million and $5.5 million in purchases of property and equipment, partially offset by $41.7 million in proceeds from the sales and maturities equipment of marketable securities. $5.5 million.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Diagnostic test revenue increased by $106.5 $114.5 million, or 54%, 38%, to $416.7 million for the year ended December 31, 2025, from $302.2 million for the year ended December 31, 2024, from $195.7 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Selling and marketing expenses increased by $6.4 $21.0 million, or 11%, 31%, to $88.4 million for the year ended December 31, 2025, from $67.4 million for the year ended December 31, 2024, from $61.0 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Adjusted net income (loss) is a non-GAAP financial measure that we define as net income (loss) adjusted for depreciation and amortization, stock-based compensation expenses, restructuring costs, impairment loss, restructuring and business exit related charges, change in fair market value of financial liabilities, transaction costs interest expense (income), net, income tax expense (benefit), net, and other (income) expense, net.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
(6)For (2)For the year ended December 31, 2024, 2025, represents transaction costs associated with the Merger Agreement, a legal settlement reserve for a certain litigation matter. matter and a sales-and-use tax refund.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
The timing of these future payments, by year, can be found in Note 11, “Purchase Commitments and Contingencies” to our consolidated financial statements in Note 10, “Purchase Commitments and Contingencies”, included within this Annual Report. statements.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new